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Abstract
GSK-3b is regarded as playing an important part in the pathogenesis of schizophrenia and the action of
psychotomimetic agents. We observed phosphorylation of molecules associated with the GSK-3b signal-
ling pathway in the rat brain after MK-801 injection, which induces a schizophrenia-like state in humans.
Ser9-GSK-3b phosphorylation was increased after injection of 1 mg/kg MK-801 in the rat frontal cortex
but not in the hippocampus or cerebellum. This increase peaked at 30 min and was maintained until
90 min after injection. The phosphorylation showed a dose-dependent increase up to 1 mg/kg MK-801,
followed by a decrease at higher dosage. Furthermore, phosphorylation of Ser473-Akt and Ser133-CREB
showed similar temporal, dose-dependent and regionally specific patterns with those of Ser9-GSK-3b.
However, phosphorylation of Dvl and Ser33-b-catenin was not affected by MK-801. These results suggest
that GSK-3b phosphorylation by MK-801 may be associated with the Akt-GSK-3b pathway rather than
with the Wnt-Dvl-GSK3b pathway.
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Introduction
Investigations into GSK-3b have focused on its roles in
intracellular signalling pathways, which regulate en-
ergy metabolism, cellular structure maintenance and
regulation of gene transcription (Grimes and Jope,
2001). While the dysfunction of GSK-3b has been sug-
gested in various medical disorders, GSK-3b inhibitors
are currently under investigations for their therapeutic
potential (Woodgett, 2003).
Dysfunction of GSK-3b has been suggested to be
related to psychiatric disorders such as schizophrenia,
bipolar disorder and Alzheimer’s disease (Beasley
et al., 2001; Grimes and Jope, 2001; Kozlovsky et al.,
2000; Nadri et al., 2003). The reduction in the protein
levels and Ser9 phosphorylation status of GSK-3b have
been reported in the post-mortem frontal cortex of
schizophrenic patients (Emamian et al., 2004). In the
frontal cortex of rats with neonatal ventral hippo-
campal lesion used as a model of schizophrenia, the
level of GSK-3b was also reduced (Nadri et al., 2003).
GSK-3b has been considered as a molecular target of
mood stabilizers such as lithium and valproate (Chen
et al., 1999; Grimes and Jope, 2001), and its phos-
phorylation is also affected by clozapine and ECS,
which are well known treatment modalities for
schizophrenia and bipolar disorder (Kang et al., 2004;
Roh et al., 2003).
GSK-3b can be phosphorylated either by Akt or the
canonical Wnt signal. Both Akt and the Wnt signal
have been implicated in GSK-3b phosphorylation by
antipsychotics. Acute haloperidol treatment has been
reported to increase the phosphorylation of Thr308-
Akt and Ser9-GSK-3b, while chronic haloperidol in-
creases both Thr308 and Ser473-Akt which leads to
the increased phosphorylation of Ser9-GSK-3b. The
same study also reported decreased levels of Akt1
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protein and the phosphorylation of Ser9-GSK-3b in the
peripheral lymphocytes and brains of schizophrenics
(Emamian et al., 2004). We, on the other hand, pre-
viously reported that clozapine increased the phos-
phorylation of Ser9-GSK-3b via the Wnt pathway,
rather than via the PI3K-Akt signalling pathway
(Kang et al., 2004).
Recently, the psychotomimetics used in animal
schizophrenic models have also been shown to phos-
phorylate GSK-3b. In the mouse frontal cortex, the
increased phosphorylation of Ser9-GSK-3b, along
with that of Thr34-DARPP-32, Ser130-DARPP-32 and
Ser133-CREB, has been reported after treatment of
psychotomimetic drugs, such as d-amphetamine,
lysergic acid diethylamide (LSD) and phencyclidine
(PCP). However, these changes were not observed
in the hippocampus or cerebellum.Hence, phosphoryl-
ation of GSK-3b appears to be a common pathway
through which diverse psychotomimetic drugs show
effect (Svenningsson et al., 2003).
The non-competitive NMDA receptor antagonist
MK-801 has psychotomimetic effects closely resem-
bling the symptoms of schizophrenia ( Javitt and
Zukin, 1991; Olney and Farber, 1995). Although
Svenningsson et al. (2003) did not directly present
results for MK-801, they commented that MK-801
seems to act through a mechanism similar to PCP
in the phosphorylation of DARPP-32 in the mouse
brain. Therefore, the phosphorylation of GSK-3b
may be increased byMK-801 injection. However, there
is a report that MK-801 reduces p-Akt levels up-
stream of GSK-3b in cortical neuronal cultures (Sutton
and Chandler, 2002). Therefore, the result reported
by Sutton and Chandler is not consistent with the
assumption based on the comment of Svenningsson
et al. (2003). This controversy also encompasses the
phosphorylation of CREB. Although Svenningsson
et al. (2003) reported that many psychotomimetics,
including PCP, increase the phosphorylation of CREB,
MK-801 was known to reduce p-CREB levels in pri-
mary striatal cultures (Dudman et al., 2003).
In this paper, we first examined whether MK-801
injection increases the phosphorylation of Ser9-GSK-3b
in the rat brain with regional specificity and in a dose-
dependent manner. Second, we investigated whether
the upstream mechanism of Ser9-GSK-3b phosphoryl-
ation is the canonical Wnt pathway and/or the Akt
pathway. Third, between the two sites phosphorylated
in Akt, Ser473 and Thr308, we determined which site
was involved inMK-801. Finally, we observedwhether
the phosphorylation of Ser133-CREB, after MK-801
injection, shows similar temporal and regional patterns
with that of Ser9-GSK-3b.
Materials and methods
Animals and drug treatment
Male Sprague–Dawley rats (150–200 g) were grouped
and maintained on a 12 h, light/dark cycle with food
and water freely available. Animals were treated in
accordance with the NIH Guide for the Care and Use
of Laboratory Animals.
MK-801 (Tocris, Ellisville, MO, USA), dissolved in
normal saline, was injected into the rats intraper-
itoneally and control animals received an equivalent
volume of normal saline. According to our previous
observation, the level of c-Fos definitely increased in
the cerebral cortex from administration of 0.25 mg/kg
MK-801, peaked with 1–2 mg/kg, and then decreased
(Ahn et al., 2002). In terms of behavioural activation,
there is a report of maximal behavioural activation
after injection of 1 mg/kg MK-801 in locomotion and
stereotyped sniffing (Andine et al., 1999), which is
in agreement with the results of our previous study
(Ahn et al., 2002). Therefore, we chose 1 mg/kg as the
dose to determine the temporal profile. To examine the
relation between MK-801 dosage and phosphoryl-
ation, we observed the level of phosphorylation at
60 min after MK-801 injection because preliminary re-
sults showed no changes in the phosphorylation after
60 min at each dose. Furthermore, there is a report that
MK-801-induced locomotion, stereotyped sniffing and
ataxia are fully and stably developed around 60 min
after MK-801 injection (Andine et al., 1999).
Western blot analysis
The brain was dissected on an ice plate. The hippo-
campus and frontal cortex were immediately hom-
ogenized in 10 vol (v/w) of pre-chilled buffer
containing 25 mM Hepes (pH 7.9), 200 mM NaCl,
1.5 mM MgCl2, 0.2% NP-40, 1 mM DTT, 0.5 mM EDTA,
1 mM PMSF, 20 mM b-glycerophosphate, 2 mM NaF,
0.1 mM Na3VO4 and 2 mg/l leupeptin. Homogenates
were centrifuged and the supernatants were boiled
with Laemmli sample buffer. Samples were fraction-
ated in 8% SDS–PAGE gel and then transferred to
nitrocellulose membranes (Schleicher & Schuell
Bioscience, Dassel, Germany). The membranes were
then incubated with Ser9-GSK-3b, Ser133-CREB,
Ser473-Akt, Thr308-Akt (Cell Signaling Technology,
Beverly, MA, USA), Ser33-b-catenin and dishevelled
(Dvl) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) specific antibody at a dilution of 1:1000 over-
night at 4 xC. The membranes were then incubated
with the anti-rabbit IgG conjugated to horseradish
peroxidase (Santa Cruz Biotechnology) and the signal
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was detected with the ECL system (Pierce, Rockford,
IL, USA). The duration of film exposure was adjusted
according to the preliminary experiments.
Results
In the rat frontal cortex, after injection of 1 mg/kgMK-
801, the phosphorylation of Ser9-GSK-3b was in-
creased from 15 min compared to the control, peaked
at 30 min and was maintained until 90 min after in-
jection ofMK-801. The phosphorylation of both Ser473-
Akt and Ser133-CREB, upstream and downstream
molecules of GSK-3b respectively, followed the same
temporal course after injection of 1 mg/kg MK-801.
However, the phosphorylation of Thr308-Akt was
not changed (Figure 1).
We examined the effect of each dose of MK-801 at
60 min after injection in the rat frontal cortex. The
phosphorylation of Ser9-GSK-3b showed a dose-
dependent increase up to 1 mg/kg MK-801, followed
by a decrease at higher dosage. Interestingly, at
8 mg/kg, a dose which clearly elicited no movement
in the rats, the level of phosphorylation was below that
of the control. The phosphorylation of Ser473-Akt
and Ser133-CREB showed parallel, dose-dependent
patterns with the phosphorylation of Ser9-GSK-3b
(Figure 2).
To clarify the upstream mechanism of Ser9-GSK-3b
phosphorylation, we also examined the mobility shift
of Dvl, as the phosphorylation of Dvl is involved with
GSK-3b phosphorylation in the canonical Wnt path-
way. However, we did not observe any change in the
mobility shift of Dvl. In addition, we also examined
the level of Ser33-b-catenin phosphorylation and the
amount of b-catenin, another downstream molecule
of Ser9-GSK-3b, in the canonical Wnt pathway, but
there was no change in the phosphorylation or amount
of b-catenin (Figure 3).
In contrast to the rat frontal cortex, we observed
no increase in the phosphorylation of Ser9-GSK-3b,
Ser473-Akt and Ser133-CREB in the rat hippocampus
and cerebellum (data not shown).
Discussion
We observed that MK-801 increased the phosphoryl-
ation of Ser9-GSK-3b in the rat brain with regional
specificity and characteristic dose-dependent pattern.
Also we observed that the phosphorylation of Ser473-
Akt and Ser133-CREB showed the same regional
specificity and similar temporal and dose-dependent
patterns as those of the phosphorylation of Ser9-GSK-
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Figure 1. The phosphorylation of GSK-3b, Akt and CREB in
the rat frontal cortex. (a) Immunoblots of rat frontal cortex
after exposure toMK-801 (1 mg/kg) for the indicated periods.
The phosphorylation of Ser9-GSK-3b, Ser473-Akt and
Ser133-CREB was increased from 15 min, peaked at 30 min
and was maintained until 90 min. (b) Quantification of
immunoblot data by densitometric analysis of band intensity.
Data are expressed as optical density and represent
means¡S.E.M. of three independent experiments. OD (optical
densities) ratio=(OD of the phosphorylation bands of the
MK-801-injected group)/(OD of the phosphorylation bands
of the vehicle-injected group). Asterisks (*) indicate
significant difference (p<0.05, Wilcoxon signed rank test).
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phosphorylation of Ser9-GSK-3b may be correlated
with that of Ser473-Akt and Ser133-CREB. Therefore,
the Akt signalling pathway may act as an upstream
mechanism of Ser9-GSK-3b phosphorylation induced
by MK-801.
To enhance the understanding of psychoses and
their treatment, it is very important to determine the
commonpathwaywhich is involved in the pathophysi-
ology of psychoses and the mechanism of psychoto-
mimetics. In a previous study by Svenningsson et al.
(2003), the increased phosphorylation of Ser9-GSK-3b
and Ser133-CREB in the rat frontal cortex was claimed
as one of the common signalling pathways alongwhich
diverse psychotomimetics act. We directly showed
that another psychotomimetic, MK-801, also induced
similar results to those of Svenningsson et al. (2003) in
terms of the phosphorylation of Ser9-GSK-3b and
Ser133-CREB. Furthermore, our observation of the re-
gional specific pattern of phosphorylation is the same
as that of Svenningsson et al. (2003).
Although the Akt-GSK-3b signalling pathway was
suggested as a critical signalling pathway for the
pathogenesis of schizophrenia and the action of anti-
psychotics (Emamian et al., 2004), the relationship be-
tween the signalling pathway of GSK-3b and the
action of psychotomimetics remains to be elucidated.
To clarify the upstream mechanism of Ser9-GSK-3b
phosphorylation, we examined the phosphorylation of
Ser473-Akt and the mobility shift of Dvl. The phos-
phorylation of GSK-3b can be affected by either the
canonical Wnt or Akt pathway. In the canonical Wnt
pathway, the binding of Wnt to the Frizzled protein
increases the phosphorylation of the adaptor protein
Dvl, which leads to the phosphorylation deactivation
of GSK-3b. Through this deactivation, the phosphoryl-
ation status of b-catenin is decreased, which releases
b-catenin from the complex of Axin, APC and b-
catenin, and the released b-catenin enters into the
nucleus (Aoki et al., 1999). In the Akt pathway, sig-
nalling events leading to the activation of Akt can
phosphorylate and thereby regulate many signal mol-
ecules including GSK-3b (Kandel and Hay, 1999).
Ser133-CREB is reported as downstream of the Akt
pathway (Du and Montminy, 1998) and also as a sub-
strate for GSK-3b (Grimes and Jope, 2001; Salas et al.,
2003), although its phosphorylation is activated
by several kinases other than GSK-3b (Lonze and
Ginty, 2002). We observed that the phosphoryl-
ation of Ser473-Akt and Ser133-CREB, showed the
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Figure 2. MK-801 dose-dependent patterns of the phosphorylation of GSK-3b, Akt and CREB in the rat frontal cortex. (a)
Immunoblots of the rat frontal cortex at 60 min after exposure to MK-801 for the indicated doses. The phosphorylation of
Ser9-GSK-3b, Ser473-Akt and Ser133-CREB was increased up to 1 mg/kg, and then decreased. (b) Quantification of
immunoblot data by densitometric analysis of band intensity. Data are expressed as optical density and represent means¡S.E.M.
of three independent experiments.
610 Y. M. Ahn et al.
dose-dependent patterns as Ser9-GSK-3b. However,
the phosphorylation of Dvl and Ser33-b-catenin, which
are representative upstream and downstream signal
transduction molecules respectively, of GSK-3b in the
canonical Wnt pathway, were not changed by MK-801
injection. Therefore, the canonical Wnt pathway does
not seem to act upstream of the MK-801-induced Ser9-
GSK-3b phosphorylation in our experimental con-
ditions. Our results suggest that the Akt-GSK-3b
pathway, rather than the canonical Wnt pathway,
may play an important role as one of the signalling
pathways for MK-801.
Akt has several phosphorylation sites. Among
them, the phosphorylation of Thr308 by PDK1 (phos-
phoinositide-dependent kinase 1) and the phos-
phorylation of Ser473 by autophosphorylation and
by uncharacterized kinases is important in Akt regu-
lation (Alessi and Cohen, 1998; Scheid and Woodgett,
2003; Sutton and Chandler, 2002; Toker and Newton,
2000). Therefore, we examined the changes in Thr308
and Ser473-Akt phosphorylation after MK-801 intra-
peritoneal injection and found that only the phos-
phorylation of Ser473-Akt was affected by MK-801 in
the rat frontal cortex. Interestingly, Kitagawa et al.
(2002) reported that the exposure of cultured neurons
to glutamate in rats induced the phosphorylation of
Ser473-Akt and Ser133-CREB but showed no change
in Thr308-Akt phosphorylation and no enhancement
in Akt kinase activity. Although MK-801 is an NMDA
receptor antagonist, these findings are quite similar to
our observations of increased phosphorylation of
Ser473-Akt and Ser133-CREB, but no change in
Thr308-Akt phosphorylation, after injection of
<8 mg/kg MK-801 in the rat frontal cortex. However,
Sutton and Chandler (2002) reported that MK-801
(10 mM) treatment in cortical neuronal culture reduces
the phosphorylation of Ser473-Akt compared to basal
levels. According to our previous study, 8 mg/kgMK-
801 pretreatment completely blocked ECS-induced
seizure and partially blocked the induction of c-Fos
(Ahn et al., 2002). In this report, a 8 mg/kg MK-801
injection also reduced the phosphorylation of Ser473-
Akt, Ser9-GSK-3b and Ser133-CREB in the rat frontal
cortex. This suggests that the MK-801 dosage is im-
portant in determining the phosphorylation of the
Akt-GSK-3b signalling pathway.
Our finding that MK-801, an NMDA receptor
antagonist, increases the phosphorylation of Ser473-
Akt seems to contradict a previous report that the
activation of the NMDA receptor increases the phos-
phorylation of Ser473-Akt (Kitagawa et al., 2002).
However, Sutton and Chandler (2002) reported that
the NMDA dose–response curve for the stimulation of
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Figure 3. Dvl mobility shift assay, and the amount and phosphorylation of b-catenin in the rat frontal cortex. (a) There was no
mobility shift of Dvl and immunoblots showed that there was no change in the phosphorylation or amount of Dvl and b-catenin.
(b) Quantification of immunoblot data by densitometric analysis of band intensity. Data are expressed as optical density and
represent means¡S.E.M. of three independent experiments.
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possibility that MK-801 may activate Ser473-Akt
through a mechanism independent of the NMDA
receptor cannot be excluded (Olney and Farber, 1995).
Taken together with our finding that MK-801 increases
the phosphorylation of Ser473-Akt, this result cannot
be explained by a simple linear relation between
NMDA receptor activity and Akt phosphorylation.
According to our observations, the phosphorylation
of Ser9-GSK-3b, Ser473-Akt and Ser133-CREB, after
injection of 1 mg/kg MK-801, was increased from
15 min, peaked at 30 min and was maintained until
90 min. This temporal pattern is basically correlated
with the temporal profile of behavioural changes that
are observed in a rat model of psychosis induced by
the psychotomimetic, MK-801. It was reported that the
first sign of locomotion and stereotyped sniffing in rats
was observed at 20–25 min after MK-801 adminis-
tration (0.2 mg/kg i.p., 60 d old; Andine et al., 1999).
Meanwhile, according to the dose-dependent pattern
in the present study, the phosphorylation peaked at
1 mg/kg. This finding also basically correlates with
the same report by Andine et al. (1999) that the rat
showed maximal behavioural activation in locomotion
and stereotyped sniffing after 1 mg/kg MK-801,
whereas with 3 mg/kg it merely showed extensive
ataxia without locomotion. Therefore, these findings
suggest that the changes in the phosphorylation may
reflect the behavioural changes induced by MK-801,
which demonstrates the importance of the phos-
phorylation of Ser9-GSK-3b in the biochemical mech-
anism of MK-801 as a psychotomimetic.
Taken together, our observations suggest that the
phosphorylation of Ser473-Akt, Ser9-GSK-3b and
Ser133-CREB may play an important role in the
mechanism of MK-801 as a psychotomimetic agent.
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